Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621098 · ClinicalTrials.gov registry record
EMPOWER-PULM (PULMonary Outcomes in Older Adults Empowered With Movement to Prevent Obesity and Weight Regain)
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 76
- Enrollment target
NCT03621098: Completed study, sponsored by Wake Forest University Health Sciences.
NCT03621098 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03621098 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to improve the understanding of the effects of weight loss on the lungs in older adults. Different types of tests to understand the effects of the EMPOWER interventions on lung function will be administered.
Primary Outcome
Number of patients who are able to undergo Pulmonary Function
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2018-11-19 |
What the finished NCT03621098 record still lists
NCT03621098 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 76 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03621098 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03621098 about?
NCT03621098 is a clinical study titled "EMPOWER-PULM (PULMonary Outcomes in Older Adults Empowered With Movement to Prevent Obesity and Weight Regain)". The purpose of this study is to improve the understanding of the effects of weight loss on the lungs in older adults. Different types of tests to understand the effects of the EMPOWER interventions on lung function will be administered.
What is the current status of trial NCT03621098?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2016-12-15. Estimated completion is 2018-11-19.
Who is sponsoring clinical trial NCT03621098?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI